Department of Radiology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, 23, Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.
Cancer Imaging. 2020 Jul 10;20(1):46. doi: 10.1186/s40644-020-00321-2.
There has been scanty data regarding the clinical significance of tumor conspicuity in pancreatic cancer. In this study, we attempted to investigate the prognostic significance of pancreatic tumor conspicuity and determine prognostic factors for postoperative recurrence in patients with surgically resected pancreatic cancer.
Between January 2011 and September 2019, 62 patients who underwent preoperative computed tomography (CT) for pancreatic cancer were retrospectively included. Two reviewers evaluated various clinical, imaging, and pathologic variables and reviewed all available medical records to determine patient outcomes after surgery. Tumor conspicuity was defined as the attenuation ratio between normal parenchyma and tumor lesions on dynamic-enhanced CT images and represented the conspicuity score. Recurrence-free survival and overall survival were investigated using Cox regression analysis.
Patient mean age was 65.9 (±11.6) years, and 56.5% were male. The median follow-up period was 11 months (range 2-138). Forty patients (64.5%) experienced postoperative recurrence, and the median time to recurrence was 6 months (range 1-101). Tumor conspicuity scores were positively correlated with both radiologic and pathologic tumor sizes (r = 0.252, 0.321, p < 0.01). Conspicuity score ≥ 2 (HR 3.8, 95% CI 1.73-8.47), elevated preoperative (HR 1.15, 95% CI; 1.02-1.28) and postoperative CA19-9 (HR 1.11, 95% CI 1.01-1.23), pathologic tumor size (HR 1.61, 95% CI 1.06-2.45), and lymphatic invasion (HR 2.76, 95% CI 1.22-6.21) were significant factors for recurrence-free survival in the multivariate analysis.
Over half of the patients with pancreatic cancer experienced postoperative recurrence (64.5%). Increased tumor conspicuity correlated with larger tumor size and postoperative recurrence.
关于胰腺癌中肿瘤显影的临床意义,数据资料较少。本研究旨在探讨胰腺肿瘤显影的预后意义,并确定手术切除胰腺癌患者术后复发的预后因素。
2011 年 1 月至 2019 年 9 月,回顾性纳入 62 例行术前 CT 检查的胰腺癌患者。两名评审员评估了各种临床、影像学和病理学变量,并查阅了所有可用的病历,以确定手术患者的预后。肿瘤显影定义为动态增强 CT 图像上正常实质与肿瘤病变之间的衰减比值,并代表显影评分。使用 Cox 回归分析评估无复发生存率和总生存率。
患者平均年龄为 65.9(±11.6)岁,56.5%为男性。中位随访时间为 11 个月(范围 2-138)。40 例(64.5%)患者发生术后复发,中位复发时间为 6 个月(范围 1-101)。肿瘤显影评分与影像学和病理学肿瘤大小均呈正相关(r=0.252,0.321,p<0.01)。显影评分≥2(HR 3.8,95%CI 1.73-8.47)、术前(HR 1.15,95%CI;1.02-1.28)和术后 CA19-9(HR 1.11,95%CI 1.01-1.23)、病理肿瘤大小(HR 1.61,95%CI 1.06-2.45)和淋巴血管侵犯(HR 2.76,95%CI 1.22-6.21)是多因素分析中无复发生存的显著因素。
超过一半的胰腺癌患者(64.5%)经历了术后复发。肿瘤显影增加与肿瘤体积增大和术后复发有关。